Clinical effect of edaravone dexborneol combined with urinary kallidinogenase in the treatment of mild-to-moderate acute thrombotic cerebral infarction

Objective To investigate the clinical effect of edaravone dexborneol combined with urinary kallidinogenase in the treatment of mild-to-moderate acute thrombotic cerebral infarction and its impact on thromboelastography parameters, von Willebrand factor (vWF), and other indicators.

Methods A total of 100 patients with mild-to-moderate acute thrombotic cerebral infarction were selected as the study subjects and randomly divided into two groups using a random number table method, with 50 cases in each group. The control group received conventional treatment (antiplatelet therapy with aspirin combined with clopidogrel), while the observation group received edaravone dexborneol combined with urinary kallidinogenase in addition to the control group's treatment. Both groups were treated for 10 days. Thromboelastography parameters clot formation time (K value), coagulation reaction time (R value), clot angle (Angle value), maximum amplitude of thrombus (MA value), and comprehensive coagulation index (CI value), vWF, platelet aggregation rate, cerebral hemodynamic indicators mean blood flow velocity and pulsatility index of the middle cerebral artery and basilar artery, oxidative stress indicators superoxide dismutase (SOD) and malondialdehyde (MDA), neurological function serum neuron-specific enolase (NSE), S100β protein, and National Institutes of Health Stroke Scale (NIHSS) score, and adverse reactions were compared between the two groups.

Results At 10 days of treatment, the K value, R value, and SOD level in the observation group were higher than those in the control group, while the Angle value, MA value, CI value, platelet aggregation rate, vWF, MDA, NSE, S100β protein levels, and NIHSS score were lower than those in the control group, with statistically significant differences (P < 0.05). At 10 days of treatment, the mean blood flow velocities of the middle cerebral artery and basilar artery in both groupswere higher than those before treatment, and the pulsatility indices were lower than those before treatment. Moreover, the mean blood flow velocity in the observation group was higher than that in the control group, and the pulsatility index was lower than that in the control group, with statistically significant differences (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.379, P=0.538).

Conclusion Edaravone dexborneol combined with urinary kallidinogenase treatment can improve thromboelastography parameters and cerebral hemodynamic indicators in patients with mild-to-moderate acute thrombotic cerebral infarction, reduce vWF levels and platelet aggregation rate, alleviate oxidative stress reactions, promote neurological function recovery, and has good safety.